{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.2","value":"144"},{"groupId":"OG001","spread":"45.0","value":"136"},{"groupId":"OG002","spread":"41.5","value":"142"},{"groupId":"OG003","spread":"24.2","value":"77.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"5"}],"units":"Participants"}],"description":"Vd/f was defined as the apparent volume of distribution, calculated as Dose/ (λz\\*AUC0-inf), uncorrected for fraction absorbed; reported normalized by participant body weight.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with normal hepatic function received Tablet A (selinexor 5 × 20 mg tablets) orally QW on Day 1 or Day 8, until PD, intolerability, or Investigator decision.","id":"OG000","title":"Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function"},{"description":"Participants with normal hepatic function received Tablet B (selinexor 1 × 100 mg tablet) orally QW on Day 1 or Day 8, until PD, intolerability, or Investigator decision.","id":"OG001","title":"Monotherapy: Tablet B (Selinexor 1 x 100 mg Tablet): Normal Hepatic Function"},{"description":"Participants with moderate hepatic function received Tablet A (selinexor 2 × 20 mg tablet) orally QW on Day 1 until PD, intolerability, or Investigator decision.","id":"OG002","title":"Monotherapy: Tablet A (Selinexor 2 X 20 mg Tablet): Moderate Hepatic Function"},{"description":"Participants with severe hepatic function received Tablet A (selinexor 2 x 20 mg tablet) orally QW on Day 1 until PD, intolerability, or Investigator decision.","id":"OG003","title":"Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"PK analysis was defined as all participants in the monotherapy part who received at least 1 dose of selinexor and had at least 1 post-dose PK measurement without important protocol deviations/violations or events thought to significantly affect the PK of selinexor (e.g., vomited at or before 6 hours; wrong dose administered; prohibited concomitant medication). Here 'Overall Number of Participants Analyzed' signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 24, 30, and 48 hours post-dose on Days 1 and 8","title":"Monotherapy: Apparent Volume of Distribution (Vd/F) of Selinexor in Participants With Normal, Moderate and Severe Hepatic Impairment","type":"SECONDARY","unitOfMeasure":"liter"}